Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Files to Begin Phase I Trial of HBV Drug

Premium

Arrowhead Research said this week that it has filed an application with Australian regulators to begin phase I testing of its hepatitis B treatment ARC-520.

Arrowhead acquired the drug through its 2011 purchase of Roche’s RNA therapeutics assets (GSN 11/27/2011). It comprises cholesterol-conjugated siRNAs against HBV and a proprietary delivery technology called dynamic polyconjugates.

Earlier this year, Arrowhead’s president and CEO said that the company plans to run two phase I studies for ARC-520 — one in healthy patients in Australia and a second, to begin before the end of 2013, in HBV-infected patients in Hong Kong.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.